Physician profile
Danil Makarov
NPI 1730226366
$1,041.35
in general payments reported to CMS, 2019-2025
10 companies · $18.30 in 2025
The $18.30 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2021: $38.71 · 2022: $26.67 · 2023: $79.12 · 2024: $173 · 2025: $18.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252 · Debt Forgiveness: $18.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.76 |
| Debt Forgiveness | $18.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $573.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.70 | 2024 | |
| Karl Storz Endoscopy-America | $132.66 | 2019 | |
| Abbvie INC. | $51.01 | 2023 | |
| Procept Biorobotics Corporation | $38.71 | 2021 | |
| Myriad Genetic Laboratories, INC. | $28.11 | 2023 | Prolaris |
| Boston Scientific Corporation | $26.67 | 2022 | |
| Kaleo, INC. | $22.94 | 2024 | Auvi-Q |
| Baxter Healthcare | $18.30 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danil Makarov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.